RecruitingPhase 3NCT05912517
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Studying Hemolytic disease due to fetomaternal alloimmunization
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- Nipocalimab(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2023 – 2029
Study locations (30)
- University of California at San Diego, La Jolla, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- UC Davis School of Medicine, Sacramento, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Advocate Children's Hospital, Park Ridge, Illinois, United States
- Riley Children s Hospital, Indianapolis, Indiana, United States
- University of Kentucky Medical Center, Lexington, Kentucky, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Midwest Fetal Care Center, Minneapolis, Minnesota, United States
- Columbia University Medical Center, New York, New York, United States
- University of North Carolina (UNC) - School of Medicine, Chapel Hill, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Lehigh Valley Hospital, Allentown, Pennsylvania, United States
- University of Texas Dell Medical School Department of Women's Health, Austin, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05912517 on ClinicalTrials.govOther trials for Hemolytic disease due to fetomaternal alloimmunization
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07194070A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global RegistryJanssen Research & Development, LLC
- RECRUITINGNCT06984445Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal AnemiaInstitute of Mother and Child, Warsaw, Poland
See all trials for Hemolytic disease due to fetomaternal alloimmunization →